Background: The haemoglobin glycation index (HGI) was
created to measure interindividual variation in glycosylated
hemoglobin (HbA1c) determined by factors other than blood
glucose concentration. The objective of this investigation was to
assess the potential role of HbA1c in exacerbating anemia and
increasing inflammation in non-diabetic patients with chronic
kidney disease (CKD) stages 4-5 not on dialysis and examine
anemia–HbA1c correlation. Methods: This prospective
investigation comprised 100 patients not on dialysis with nondiabetic CKD stages 4-5. The study was conducted at the
Internal Medicine and Nephrology Department of Zagazig
General Hospital. Patients were randomly selected and divided
into two equal categories depending on CKD stage: Group I
included individuals with CKD Stage 4, while Group II included
individuals with CKD Stage 5. In accordance with HGI value,
the following groups were established: Low HGI (n=36),
Moderate HGI (n=28), and High HGI (n=36). Group A (n=32)
had HbA1c (%)